RecruitingPhase 1NCT07636928

Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184

A Phase 1, Open-Label, Single Dose Study to Assess the Absolute Bioavailability, Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]VH4524184 in Healthy Participants

Sponsor

ViiV Healthcare

Enrollment

9 participants

Start Date

Jun 4, 2026

Study Type

INTERVENTIONAL

Conditions

HIV Infections

Summary

The purpose of the study is to assess the bioavailability, mass balance, pharmacokinetics, metabolism and excretion of radiolabeled (14C) VH4524184.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called VH4524184, a drug called [14C]VH4524184, and others for people with hiv infections. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVH4524184

One dose of VH4524184 is administered to participants at time zero on Day 1 (Period 1).

DRUG[14C]VH4524184 microdose

A radiolabelled microdose of \[14C\]VH4524184 is administered 2.5 hours after VH4524184 dose administration on Day 1 (Period1).

DRUG[14C]VH4524184

One dose of radiolabelled \[14C\]VH4524184 is administered to participants at Day 15 (Period 2).

Locations(1)

GSK Investigational Site

Groningen, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07636928

Related Trials

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

NCT07202546123 locations

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

NCT0747377831 locations

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

NCT076829613 locations

A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants

NCT075255441 location

Sexual Health Advocacy for Guys - a Text Messaging-based HIV Prevention Program for Guys Who Are Into Guys

NCT062303672 locations